- Conditions
- Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
- Interventions
- Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 32
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Core Biopsy, Fluorouracil, Irinotecan, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quemliclustat, Zimberelimab
- Procedure · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Advanced Solid Tumors
- Interventions
- zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 9
- States / cities
- Riverside, California • Roseville, California • Newark, Delaware + 5 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat, Etrumadenant, Modified FOLFIRINOX
- Radiation · Drug
- Lead sponsor
- Gulam Manji
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Lake Success, New York • New York, New York • Chapel Hill, North Carolina + 2 more
- Conditions
- Glioblastoma
- Interventions
- Zimberelimab, Domvanalimab, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- San Francisco, California • New Haven, Connecticut • Boston, Massachusetts
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- AB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more
- Conditions
- Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction
- Interventions
- Zimberelimab, Domvanalimab, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
- Interventions
- Domvanalimab, Etrumadenant, Zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Whittier, California • Englewood, Florida + 15 more
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
- Interventions
- AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more
- Conditions
- Urothelial Carcinoma, Metastatic Cancer
- Interventions
- Pemetrexed, Zimberelimab, Etrumadenant
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer
- Interventions
- Etrumadenant, Zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
- Interventions
- Etrumadenant, Zimberelimab, Quemliclustat, Enzalutamide, Docetaxel, SG
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 17
- States / cities
- Cerritos, California • Encino, California • Orange, California + 14 more
- Conditions
- Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma
- Interventions
- Zimberelimab, Domvanalimab
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas, Adenosquamous Carcinoma of the Pancreas
- Interventions
- ZIMBERELIMAB, DOMVANALIMAB, APX005M, FOLFIRI
- Drug
- Lead sponsor
- James Cleary, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Cisplatin, Computed Tomography, Durvalumab, Fluorouracil, Gemcitabine, Irinotecan, Leucovorin, Ligritinib, Magnetic Resonance Imaging, Oxaliplatin, Zimberelimab
- Procedure · Drug · Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Melanoma
- Interventions
- Zimberelimab, Domvanalimab
- Drug
- Lead sponsor
- Diwakar Davar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
- Interventions
- Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Fort Wayne, Indiana • Lexington, Kentucky + 3 more
- Conditions
- Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
- Interventions
- Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
- Interventions
- SRF617, etrumadenant, zimberelimab
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Miami, Florida • Ann Arbor, Michigan • Las Vegas, Nevada + 4 more
- Conditions
- Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
- Interventions
- Gemcitabine, Cisplatin, Zimberelimab, Quemliclustat
- Drug
- Lead sponsor
- Nataliya Uboha
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Ann Arbor, Michigan • New Brunswick, New Jersey + 1 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,021 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 11
- States / cities
- Whittier, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
- Conditions
- Oligometastatic Prostate Cancer
- Interventions
- Quemliclustat, Etrumadenant, Zimberelimab, Stereotactic Body Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Catherine Spina
- Other
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Upper Gastrointestinal Tract Adenocarcinoma
- Interventions
- Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 31
- States / cities
- Los Angeles, California • Orange, California • Santa Monica, California + 24 more
- Conditions
- Solid Tumor, Unspecified, Adult
- Interventions
- Domvanalimab, Zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Hinsdale, Illinois • Huntersville, North Carolina + 3 more